These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33961490)

  • 1. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework.
    Wang W; Li E; Campbell K; McBride A; D'Amato S
    JCO Oncol Pract; 2021 Aug; 17(8):e1139-e1149. PubMed ID: 33961490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
    Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
    Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
    Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
    Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
    Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
    PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
    Li E; Mezzio DJ; Campbell D; Campbell K; Lyman GH
    JCO Oncol Pract; 2021 Aug; 17(8):e1235-e1245. PubMed ID: 33793342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
    Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
    BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.